Volume 95 Issue 17 | p. 12 | Concentrates
Issue Date: April 24, 2017

Novartis licenses diabetes treatment

Department: Business
Keywords: nanomedicines, diabetes, Novartis

Novartis has licensed rights to a type 1 diabetes drug being developed by Parvus Therapeutics, which makes nanomedicines to halt or reverse autoimmune diseases. Parvus’s diabetes products, called T1D Navacims, are formed by conjugating iron oxide nanoparticles with copies of a peptide derived from a pancreatic autoantigen. Navacims reprogram pathogenic T cells into beneficial cells that suppress autoimmune-disease-causing immune cells.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment